• Home
  • In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study.

In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study.

Author List
Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, Kim YH, Hoppe RT, Knox SJ, Shin LK, Wapnir I, Tibshirani RJ, Levy R
Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Publication ID (Profile URL)
https://researcherprofiles.org/profile/1477984
Publication Year
2010
PubMed ID
20697067
Publication Title
Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, Kim YH, Hoppe RT, Knox SJ, Shin LK, Wapnir I, Tibshirani RJ, Levy R. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol. 2010 Oct 01; 28(28):4324-32.